Mechanistic Physiologically Based Pharmacokinetic Modeling to Predict CYP3A4-Mediated Drug–Drug Interactions of Flumatinib as Both a Victim and a Perpetrator
Muyesaier Alifu, Xue Chu, Xinyan Zhu, Wen Yao Mak, Aole Zheng, Chunyang Pan, Qingfeng He, Xiao Zhu, Zheng Kuai, Xiaoqiang Xiang · 2026
Read Mechanistic Physiologically Based Pharmacokinetic Modeling to Predict CYP3A4-Mediated Drug–Drug Interactions of Flumatinib as Both a Victim and a Perpetrator by Muyesaier Alifu, Xue Chu, Xinyan Zhu, Wen Yao Mak, Aole Zheng, Chunyang Pan, Qingfeng He, Xiao Zhu, Zheng Kuai, Xiaoqiang Xiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13172622.txt.
Description
Muyesaier Alifu and co-authors present a 2026 pharmacology study predicting how the leukemia drug flumatinib interacts with other medicines. The drug is cleared mainly by a liver enzyme called CYP3A4, and it also slows that same enzyme over time. Both traits make clashes with other drugs likely, yet clinical testing of every pairing is impossible.
The team fed lab measurements into a whole-body computer model built for Chinese patients. The model reproduced real drug levels well. Simulations showed flumatinib barely changes other drugs' levels, but strong blockers of the enzyme raised its own levels about twelvefold, while a strong booster drug cut them steeply. The authors advise caution when pairing it with such medicines.
Catalog record
| CREATOR | Muyesaier Alifu, Xue Chu, Xinyan Zhu, Wen Yao Mak, Aole Zheng, Chunyang Pan, Qingfeng He, Xiao Zhu, Zheng Kuai, Xiaoqiang Xiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 63 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |